Cladribine
Brand name: Mavenclad
Rank #444 of 500 drugs by total cost
$17.5M
Total Cost
228
Total Claims
$17.5M
Total Cost
13
Prescribers
$77K
Cost per Claim
60
Beneficiaries
422
30-Day Fills
$1.3M
Avg Cost/Provider
18
Avg Claims/Provider
About Cladribine
Cladribine (sold as Mavenclad) was prescribed 228 times by 13 Medicare Part D providers in 2023, costing the program $17.5M. At $77K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 441 | Rufinamide (Rufinamide) | $18.0M | 8,793 |
| 442 | Istradefylline (Nourianz) | $17.8M | 7,061 |
| 443 | Encorafenib (Braftovi) | $17.6M | 1,209 |
| 444 | Cladribine (Mavenclad) | $17.5M | 228 |
| 445 | Enalapril Maleate (Enalapril Maleate) | $17.5M | 673,317 |
| 446 | Vismodegib (Erivedge) | $17.4M | 1,317 |
| 447 | Anastrozole (Anastrozole) | $17.4M | 626,025 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology